CoChat
Sign Up
Cited by 79Protein Kinase Regulation and GTPase SignalingProtein Tyrosine PhosphatasesMelanoma and MAPK Pathways

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Activation of JNK3α1 Requires both MKK4 and MKK7: Kinetic Characterization of in Vitro Phosphorylated JNK3α1

Lisnock, JeanMarie, Griffin, Patrick, Calaycay, Jimmy, Frantz, Betsy, Parsons, Janey, O'Keefe, Stephen J., LoGrasso, Philip·2000·Biochemistry
DOI 10.1021/bi992410+
Open this paper in CoChat — free account

Abstract

JNK3 alpha 1 is predominantly a neuronal specific MAP kinase that is believed to require, like all MAP kinases, both threonine and tyrosine phosphorylation for maximal enzyme activity. In this study we investigated the in vitro activation of JNK3 alpha 1 by MAP kinase kinase 4 (MKK4), MAP kinase kinase 7 (MKK7), and the combination of MKK4 + MKK7. Mass spectral analysis showed that MKK7 was capable of monophosphorylating JNK3 alpha 1 in vitro, whereas both MKK4 and MKK7 were required for bisphosphorylation and maximal enzyme activity. Measuring catalysis under Vmax conditions showed MKK4 + MKK7-activated JNK3 alpha 1 had Vmax 715-fold greater than nonactivated JNK3 alpha 1 and MKK7-activated JNK3 alpha 1 had Vmax 250-fold greater than nonactivated JNK3 alpha 1. In contrast, MKK4-activated JNK3 alpha 1 had no increase in Vmax compared to nonactivated levels and had no phosphorylation on the basis of mass spectrometry. These data suggest that MKK7 was largely responsible for JNK3 alpha 1 activation and that a single threonine phosphorylation may be all that is needed for JNK3 alpha 1 to be active. The steady-state rate constants kcat, Km(GST-ATF2++), and Km(ATP) for both monophosphorylated and bisphosphorylated JNK3 alpha 1 were within 2-fold between the two enzyme forms, suggesting the addition of tyrosine phosphorylation does not affect the binding of ATF2, ATP, or maximal turnover. Finally, the MAP kinase inhibitor, SB203580, had an IC50 value approximately 4-fold more potent on the monophosphorylated JNK3 alpha 1 compared to the bisphosphorylated JNK3 alpha 1, suggesting only a modest effect of tyrosine phosphorylation on inhibitor binding.

Overview

Integrity signals

Registry

Crossref · 10.1021/bi992410+

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Tyr phosphorylation adds 25% activity by binding the C-lobe and further locking the active interlobe conformer.

    “Phosphorylation of Tyr adds an additional 25% activity by binding to the C-lobe and further locking in the active interlobe conformer.”

    From Structural Mechanisms of Allostery and Autoinhibition in JNK Family Kinases (2012) · cites this paper as Lisnock et al., 2000

  • After Thr phosphorylation, a movement makes Tyr accessible for phosphorylation by MKK7.

    “Indeed, this has been shown biochemically for JNK3 because it was suggested that once Thr is phosphorylated, a movement occurred so that Tyr is now accessible for phosphorylation by MKK7 (Lisnock et al., 2000).”

    From Structural Mechanisms of Allostery and Autoinhibition in JNK Family Kinases (2012) · cites this paper as Lisnock et al., 2000

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 26

  1. Ip Y. T., 1998, Curr. Opin. Cell Biol. 10, 205−219
  2. Minden A., 1997, Biochim. Biophys. Acta, 1333
  3. Yang D. D., 1997, Nature 389, 865−870
  4. Hibi M., 1993, Genes Dev. 7, 2135−2148
  5. Derijard B., 1994, Cell 76, 1025−1037
  6. Gupta S., 1996, EMBO J., 15
  7. Zhang Y., 1998, Proc. Natl. Acad. Sci. U.S.A. 95, 2586−2591
  8. Xia Z., 1995, Science 270, 1326−1331
  9. Yang D., 1997, Proc. Natl. Acad. Sci. U.S.A. 94, 3004−3009
  10. Lu X., 1997, J. Biol. Chem., 272
  11. Holland P. M., 1997, J. Biol. Chem., 272
  12. Lawler S., 1998, Curr. Biol. 8, 1387−1390
  13. LoGrasso P. V., 1997, Biochemistry 36, 10422−10427
  14. Leatherbarrow R. J., 1992, GraFit, version 3.0
  15. Derijard B., 1995, Science 267, 682−685
  16. Tournier C., 1997, Proc. Natl. Acad. Sci. U.S.A. 94, 7337−7342
  17. Jiang Y., 1996, J. Biol. Chem., 271
  18. Lisnock J. M., 1998, Biochemistry 37, 16573−16581
  19. Frantz B., 1998, Biochemistry 37, 13846−13853
  20. Canagarajah B., 1997, Cell 90, 859−869
  21. DiDonato J. A., 1997, Nature 388, 548−554
  22. Mercurio F., 1997, Science 278, 860−866
  23. Whitmarsh A. J., 1998, TIBS 23, 481−485
  24. Anderson, 1997, D. (1997)
  25. Young P. R., 1997, J. Biol. Chem., 272
  26. Abbreviations, activating transcription factor 2

Cited by

Sorted by citations

Related

Metadata

Authors
Lisnock, J., Griffin, P., Calaycay, J., Frantz, B., Parsons, J., O'Keefe, S. J., & LoGrasso, P.
Affiliations
  • Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
  • Departments of Molecular Design and Diversity, and Immunology and Rheumatology, Merck Research Laboratories, P.O. Box 2000, Rahway, New Jersey 07065
Corresponding author
LoGrasso, Philip
ORCID
Griffin, Patrick
Venue
Biochemistry
Publisher
American Chemical Society (ACS)
Published
2000-02-25
Volume
39
Issue
11
Pages
3141-3148
ISSN
  • 0006-2960 (ISSN-L)
  • 1520-4995
DOI
10.1021/bi992410+
OpenAlex
W2240139143
Cited by
79
References
12
Citations by year
2026: 1 · 2025: 2 · 2024: 3 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 4 · 2018: 1 · 2017: 2 · 2016: 4 · 2015: 4 · 2013: 2 · 2012: 7
FWCI
1.69
Type
journal article
Language
en
Open access
closed
Locations
  • Biochemistry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Keywords
MAPK activation, MKK4, MKK7, MAP kinase kinase, threonine phosphorylation, tyrosine phosphorylation, enzyme kinetics, Vmax, SB203580
MeSH terms
Adenosine Triphosphate, Binding Sites, Cloning, Molecular, Drug Synergism, Enzyme Activation, Enzyme Inhibitors, Humans, Imidazoles, Kinetics, Phosphorylation, Protein Kinases, Protein-Tyrosine Kinases, Pyridines, Recombinant Fusion Proteins, Transcription Factors, Mutagenesis, Insertional, Protein Serine-Threonine Kinases, Cyclic AMP Response Element-Binding Protein, Phosphotyrosine, Mitogen-Activated Protein Kinases, Mitogen-Activated Protein Kinase Kinases, Mitogen-Activated Protein Kinase 10, MAP Kinase Kinase 4, MAP Kinase Kinase 7, Activating Transcription Factor 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review